- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05675917
MacuTest Website for Personalized AMD Risk Prediction and Prevention (MACUTEST)
Feasibility and Acceptability of the MacuTest Website for Personalized AMD Risk Prediction and Prevention: Pilot Study
Study Overview
Detailed Description
AMD is the leading cause of blindness in industrialized countries. Current treatments only address the neovascular form and do not always prevent vision loss. This multifactorial pathology involves both genetic factors (more than 50 loci identified) and environmental factors. The genes identified suggest an important contribution of inflammation and innate immunity as well as lipid metabolism in the physiopathology of AMD. As a potential target for preventive actions, the role of lifestyle has also been the subject of much work. Thus, epidemiological studies have identified smoking as an important risk factor. The role of nutrition and metabolism in ocular aging is of growing interest, with hypotheses focusing more specifically on the joint effect of antioxidants and lipids. It is therefore important to develop prevention strategies. In this context, it is necessary to be able to identify at an early stage those people most at risk of developing AMD, in order to propose interventions aimed at reducing the risk of visual loss (reinforced ophthalmological follow-up for rapid detection and treatment of neovascular forms, lifestyle recommendations, nutritional supplementation, etc.).
During the baseline (V1) and the 12-months follow-up (V3) visits, lifestyle data (tobacco, diet, education) will be collected within online self-questionnaires on the MacuTest platform. Ophthalmological examination with evaluation of retinal anomalies, blood pressure, and saliva collection (inclusion only) for genetic testing will be perform by the ophthalmologist.
At the 6-months follow-up visit (V2), the ophthalmologist will give the participant the results of the genetic test and explanations and interpretation of the results he or she deems necessary.
At the 12-months follow-up visit (V3), the participant will fill in a questionnaire to evaluate the MacuTest platform.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jean-François KOROBELNIK, MD, PhD
- Phone Number: +335 57 82 12 16
- Email: jean-francois.korobelnik@chu-bordeaux.fr
Study Contact Backup
- Name: Bénédicte MERLE, PhD
- Phone Number: +335 57 57 12 36
- Email: benedicte.merle@u-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France
- CHU Bordeaux
-
Contact:
- Jean-François KOROBELNIK, MD, PhD
- Phone Number: +335 57 82 12 16
- Email: jean-francois.korobelnik@chu-bordeaux.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged 65 years and older of European geographic origin
- Presence of early signs of AMD (drusen and/or pigment abnormalities) and/or parents with advanced AMD.
- Absence of any advanced form of AMD (atrophic or neovascular AMD).
- Patient who can read, understand and speak French.
- Patient with access to the MacuTest internet platform throughout the study (telephone, tablet, computer).
- Patient with the ability and willingness to carry out all planned visits and assessments.
- Patient with health insurance.
- Signed informed consent.
Exclusion Criteria:
- Presence of a severe ocular pathology that prevents an examination of the fundus.
- Patient with a history of a medical condition that, in the opinion of the investigator, would prevent the completion of scheduled study visits and completion of the study.
- Adult under legal protection or residing in a health or social institution.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MacuTest website
The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform. The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient. The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet). |
The MacuTest platform will be used to collect the data needed to predict AMD risk. AMD risk prediction is evaluated by a mathematical algorithm based on the data collected and integrated into the platform. The ophthalmologist will fill in the ophthalmologist questionnaire in the platform with data on the fundus and blood pressure, after examining the patient. The patient will fill in the lifestyle questionnaires (nutrition, smoking, gender, year of birth, level of education) with his personal equipment (computer, smartphone or tablet). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
estimation of AMD risk
Time Frame: Month 6
|
Percentage of participants who received an estimation of their risk of AMD
|
Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Socio-demographic characteristics
Time Frame: baseline
|
Socio-demographic characteristics (age, gender, education level)
|
baseline
|
Lifestyle characteristics
Time Frame: baseline
|
Lifestyle characteristics (tobacco use, diet quality)
|
baseline
|
Ophthalmological characteristics
Time Frame: baseline
|
Ophthalmological characteristics (presence of drusen, pigmentary abnormalities, advanced AMD in each eye)
|
baseline
|
Genetic risk
Time Frame: baseline
|
Evaluated by the presence or not of the following variants: CFH_rs187328863 ; CFH_rs570618 ; CFH_rs148553336 ; CFH_rs10922109 ; CFH_rs35292876 ; CFH_rs121913059 ; CFH_rs61818925 ; CFH_rs191281603 ; COL4A3_rs11884770 ; ADAMTS9_rs62247658 ; COL8A1_rs140647181 ; COL8A1_rs55975637 ; CFI_rs10033900 ; CFI_rs141853578 ; PRLR_SPEF2_rs114092250 ; C9_rs62358361 ; C2_rs144629244 ; C2_rs429608 ; C2_rs181705462 ; C2_rs114254831 ; C2_rs943080 ; PILRB_rs7803454 ; KMT2E_rs1142 ; TNFRSF10A_rs79037040 ; MIR6130_rs10781182 ; TGFBR1_rs1626340 ; ABCA1_rs2740488 ; ARHGAP21_rs12357257 ; ARMS2_rs3750846 ; RDH5_rs3138141 ; ACAD10_rs61941274 ; B3GALTL_rs9564692 ; RAD51B_rs61985136 ; RAD51B_rs2842339 ; LIPC_rs2043085 ; LIPC_rs2070895 ; CETP_rs17231506 ; CETP_rs5817082 ; CTRB2_rs72802342 ; TMEM97_rs11080055 ; NPLOC4_rs6565597 ; C3_rs12019136 ; C3_rs147859257 ; C3_rs2230199 ; APOE_rs429358 ; APOE_rs73036519 ; C20orf85_rs201459901_ ; SYN3_rs5754227 ; SLC16A8_rs8135665 ;
|
baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2022/46
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Macular Degeneration
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationChina
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular Degeneration
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hoffmann-La RocheRecruitingNeovascular Age Related Macular Degeneration | nAMDChina
-
Centre Hospitalier Intercommunal CreteilCompletedMacular Degeneration Exudative Eye Left | Macular Degeneration Exudative Eye RightFrance
-
University of Modena and Reggio EmiliaCompletedMacular Degeneration Advanced | Macular Degeneration, Dry | Macular Degeneration, Senile | Macular Scar | Macular Degeneration NonexudativeItaly
-
Shanghai Refreshgene Technology Co., Ltd.RecruitingNeovascular Age-related Macular DegenerationChina
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of
Clinical Trials on MacuTest platform
-
Universidade Federal de PernambucoUnknownExercise | Kidney TransplantationBrazil
-
Kafrelsheikh UniversityCompletedPeri-implant Mucositis | Dental Implant FailedEgypt
-
University of GeorgiaEmory UniversityActive, not recruitingCerebral Palsy, SpasticUnited States
-
Aristotle University Of ThessalonikiRegion Stockholm; Hospital Universitario La Fe; University of GlasgowCompleted
-
Baylor College of MedicineBioSensicsRecruitingCognitive Impairment | Dementia | Mild Cognitive Impairment | Memory LossUnited States
-
Sun Yat-sen UniversityRecruiting
-
University of LouisvilleCompleted
-
Auris Health, Inc.Terminated
-
Reproductive Medicine Associates of New JerseyCompleted
-
Universidade Estadual do Norte do ParanáConselho Nacional de Desenvolvimento Científico e TecnológicoRecruitingEffects of Whole Body Vibration in Different Devices on Bone and Muscle Mass in Postmenopausal WomenQuality of Life | Physical Functional Performance | Bone Density | Accidental Falls | MusclesBrazil